| Susan Beth Frommeyer, MD | |
|
2004 Cumberland Ave, Middlesboro, KY 40965-1299 | |
| (606) 248-3015 | |
| (606) 248-3024 |
| Full Name | Susan Beth Frommeyer |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 27 Years |
| Location | 2004 Cumberland Ave, Middlesboro, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568525970 | NPI | - | NPPES |
| 64077357 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 38437 (Kentucky) | Primary |
| 207VX0000X | Obstetrics & Gynecology - Obstetrics | 38437 (Kentucky) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Amg-hillside Llc | 9436240017 | 22 |
News Archive
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
For decades, University of Michigan teams have tackled some of the world's toughest health challenges through research, education and global partnership.
In an unprecedented move, the California Academy of Sciences today will induct two scientists from the Gladstone Institutes', President R. Sanders "Sandy" Williams, MD, and Investigator Katherine Pollard, PhD, as Academy Fellows, bestowing yet another honor on two of San Francisco's most esteemed scientists.
MDI has released a major enhancement to Viewpoint Analytics, a powerful web-based healthcare data warehousing, management, and reporting solution. Among the biggest additions to Viewpoint's suite of capabilities, MDI has integrated McKesson's CareEnhance Disease Monitor solution, improved Viewpoint's innovative medical risk scoring, and enhanced overall reporting speed and performance through data cubing.
Going back in time to compare evolutionary changes in several thousand generations of E. coli, a University of Houston biologist hopes to one day be able to isolate a bacterial pathogen and predict the likelihood it will become resistant to a particular antibiotic.
› Verified 3 days ago
| Entity Name | Fort Sanders Perinatal Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003811381 PECOS PAC ID: 3577505536 Enrollment ID: O20050614001362 |
News Archive
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
For decades, University of Michigan teams have tackled some of the world's toughest health challenges through research, education and global partnership.
In an unprecedented move, the California Academy of Sciences today will induct two scientists from the Gladstone Institutes', President R. Sanders "Sandy" Williams, MD, and Investigator Katherine Pollard, PhD, as Academy Fellows, bestowing yet another honor on two of San Francisco's most esteemed scientists.
MDI has released a major enhancement to Viewpoint Analytics, a powerful web-based healthcare data warehousing, management, and reporting solution. Among the biggest additions to Viewpoint's suite of capabilities, MDI has integrated McKesson's CareEnhance Disease Monitor solution, improved Viewpoint's innovative medical risk scoring, and enhanced overall reporting speed and performance through data cubing.
Going back in time to compare evolutionary changes in several thousand generations of E. coli, a University of Houston biologist hopes to one day be able to isolate a bacterial pathogen and predict the likelihood it will become resistant to a particular antibiotic.
› Verified 3 days ago
| Entity Name | Amg-hillside Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710105499 PECOS PAC ID: 9436240017 Enrollment ID: O20070810000665 |
News Archive
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
For decades, University of Michigan teams have tackled some of the world's toughest health challenges through research, education and global partnership.
In an unprecedented move, the California Academy of Sciences today will induct two scientists from the Gladstone Institutes', President R. Sanders "Sandy" Williams, MD, and Investigator Katherine Pollard, PhD, as Academy Fellows, bestowing yet another honor on two of San Francisco's most esteemed scientists.
MDI has released a major enhancement to Viewpoint Analytics, a powerful web-based healthcare data warehousing, management, and reporting solution. Among the biggest additions to Viewpoint's suite of capabilities, MDI has integrated McKesson's CareEnhance Disease Monitor solution, improved Viewpoint's innovative medical risk scoring, and enhanced overall reporting speed and performance through data cubing.
Going back in time to compare evolutionary changes in several thousand generations of E. coli, a University of Houston biologist hopes to one day be able to isolate a bacterial pathogen and predict the likelihood it will become resistant to a particular antibiotic.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Susan Beth Frommeyer, MD 501 19th St., Suite 401, Knoxville, TN 37916-1839 Ph: (865) 541-1975 | Susan Beth Frommeyer, MD 2004 Cumberland Ave, Middlesboro, KY 40965-1299 Ph: (606) 248-3015 |
News Archive
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
For decades, University of Michigan teams have tackled some of the world's toughest health challenges through research, education and global partnership.
In an unprecedented move, the California Academy of Sciences today will induct two scientists from the Gladstone Institutes', President R. Sanders "Sandy" Williams, MD, and Investigator Katherine Pollard, PhD, as Academy Fellows, bestowing yet another honor on two of San Francisco's most esteemed scientists.
MDI has released a major enhancement to Viewpoint Analytics, a powerful web-based healthcare data warehousing, management, and reporting solution. Among the biggest additions to Viewpoint's suite of capabilities, MDI has integrated McKesson's CareEnhance Disease Monitor solution, improved Viewpoint's innovative medical risk scoring, and enhanced overall reporting speed and performance through data cubing.
Going back in time to compare evolutionary changes in several thousand generations of E. coli, a University of Houston biologist hopes to one day be able to isolate a bacterial pathogen and predict the likelihood it will become resistant to a particular antibiotic.
› Verified 3 days ago
Dr. John C Stitt, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2004 Cumberland Ave, Middlesboro, KY 40965 Phone: 606-248-3015 Fax: 606-248-3024 |